Repligen Corporation

NasdaqGS:RGEN Stock Report

Market Cap: US$9.1b

Repligen Future Growth

Future criteria checks 4/6

Repligen is forecast to grow earnings and revenue by 44.4% and 14.2% per annum respectively. EPS is expected to grow by 43.6% per annum. Return on equity is forecast to be 6.1% in 3 years.

Key information

44.4%

Earnings growth rate

43.56%

EPS growth rate

Life Sciences earnings growth15.2%
Revenue growth rate14.2%
Future return on equity6.13%
Analyst coverage

Good

Last updated28 Oct 2025

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Jul 29
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Repligen: Long-Term Growth Gem Suffers Some Setbacks

Jun 08
User avatar

Biomanufacturing Expansion Will Create New Global Opportunities

Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.

Repligen: Ongoing Bioprocessing Market Recovery

Mar 20

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Feb 12
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 12

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Nov 08
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Repligen Stock: Still Quite Overvalued

May 30

Earnings and Revenue Growth Forecasts

NasdaqGS:RGEN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20279551071862729
12/31/20268267613318818
12/31/2025732508714912
6/30/2025674-14103132N/A
3/31/2025650-23117146N/A
12/31/2024634-26142175N/A
9/30/2024634-8131165N/A
6/30/20246209119155N/A
3/31/202462024110147N/A
12/31/20236323675114N/A
9/30/202365310197147N/A
6/30/202371212451149N/A
3/31/202376115446160N/A
12/31/202280218639172N/A
9/30/202280116615160N/A
6/30/202277915941141N/A
3/31/202273414642133N/A
12/31/202167112848119N/A
9/30/20215931193584N/A
6/30/20215091004083N/A
3/31/2021433803262N/A
12/31/2020366603663N/A
9/30/2020327444465N/A
6/30/2020302314266N/A
3/31/2020286234367N/A
12/31/2019270214467N/A
9/30/2019253233455N/A
6/30/2019233273453N/A
3/31/201921021N/A41N/A
12/31/201819417N/A33N/A
9/30/201818423N/A42N/A
6/30/201817123N/A21N/A
3/31/201815529N/A18N/A
12/31/201714128N/A17N/A
9/30/201712521N/A4N/A
6/30/201711318N/A5N/A
3/31/201711013N/A12N/A
12/31/201610512N/A8N/A
9/30/20161007N/A9N/A
6/30/2016968N/A17N/A
3/31/2016888N/A14N/A
12/31/2015849N/A15N/A
9/30/2015789N/A13N/A
6/30/2015748N/A13N/A
3/31/2015687N/A8N/A
12/31/2014648N/A18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: RGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RGEN is expected to become profitable in the next 3 years.

Revenue vs Market: RGEN's revenue (14.2% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: RGEN's revenue (14.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (6.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/28 11:15
End of Day Share Price 2025/10/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Repligen Corporation is covered by 31 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Robert WassermanBenchmark Company
Hugo SolvetBNP Paribas